GH Secretagogue Research Stack — Dual-Pathway Pulsatile GH Release
Reviewed by the BestHealingPeptides Editorial Team ·
Exploit the synergistic dual-pathway activation of pituitary somatotrophs — GHRH-receptor (Gαs/cAMP) plus GHSR-1a ghrelin-receptor (Gq/PLC/Ca²⁺) — to produce GH pulses materially larger than either monotherapy while preserving the physiological pulsatile pattern.
Components
Protocol notes
This is a research-only stack. None of the components is licensed as a medicine in the UK; combined administration to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012. All three peptides fall under WADA S2 and are prohibited for athletes. The canonical research-chemical-community protocol pairs CJC-1295 no-DAC (NOT the DAC variant — the long-acting variant abolishes pulsatility, which is the principal pharmacological rationale of the stack) with ipamorelin, with sermorelin as an alternative GHRH-analogue choice for researchers preferring the prototype GHRH 1-29 sequence over the protease-stabilised CJC-1295 analogue.
Mechanistic rationale — why dual-pathway synergy works
Anterior-pituitary somatotrophs express two distinct receptors that drive growth-hormone vesicle exocytosis through different signalling pathways. The GHRH receptor (Gαs-coupled, cAMP/PKA cascade) is the principal physiological control point for pulsatile GH release, activated by hypothalamic GHRH neurons. The GHSR-1a ghrelin receptor (Gq-coupled, PLC/IP₃/Ca²⁺ cascade) is the physiological control point for the ghrelin-driven appetite and GH-modulating effects of the gut-brain axis. The two pathways converge on GH-vesicle exocytosis but do not share intracellular signalling — they are pharmacologically independent and additive. Combined administration of a GHRH-receptor agonist (CJC-1295 no-DAC or sermorelin) with a GHSR-1a agonist (ipamorelin) produces GH pulses 2- to 4-fold larger than either monotherapy at equivalent doses. Additional synergy comes from GHSR-1a-mediated suppression of somatostatin tone, removing the brake on GHRH-driven GH release. The combined-stack pharmacology is the foundation of every modern research approach to maximising endogenous GH release while preserving the physiological pulsatile pattern — a critical distinction from chronic recombinant somatropin replacement.
Component selection — DAC vs no-DAC vs sermorelin
The GHRH-analogue component choice is critical to the stack's pharmacological identity. CJC-1295 no-DAC (identical to Modified GRF 1-29) has a ~30-minute half-life that preserves pulsatile GH release; CJC-1295 DAC has a 6-8 day half-life through covalent albumin binding that abolishes pulsatility and produces sustained non-pulsatile elevation. The dual-pathway pulsatile-preservation rationale of this stack requires the no-DAC variant; using the DAC variant fundamentally changes the pharmacology to sustained-elevation, defeating the purpose of pairing with a short-acting GHRP. Sermorelin (the unmodified native GHRH 1-29 with ~5-12 minute half-life) is an alternative GHRH-analogue choice with the deepest clinical-trial safety record from the Geref era and the most strictly pulsatile pattern, at the cost of requiring more frequent administrations. Ipamorelin is the GHRP-class component of choice for clean GH-axis isolation given its unique selectivity profile (no cortisol/prolactin spillover) within the GHRP class — alternatives (GHRP-2, GHRP-6, hexarelin) all have notable off-target anterior-pituitary effects that complicate research endpoints.
Endpoint suggestions
Pharmacodynamic endpoints: 24-hour pulsatile GH profiling (frequent sampling, typically every 10-20 minutes for 12-24 hours) to characterise pulse amplitude, frequency, and area-under-curve; serum IGF-1 and IGFBP-3 as integrated GH-axis readouts; ALS (acid-labile subunit) as additional integrated readout. Body-composition endpoints (DEXA for lean and fat mass distribution) in chronic studies. Metabolic endpoints: fasting glucose, HOMA-IR for insulin sensitivity monitoring (GH-axis activation reduces insulin sensitivity); HbA1c for longer-duration studies. Off-target pituitary endpoints to confirm clean GH-axis activation: morning cortisol, prolactin — both expected to be unchanged with the ipamorelin-containing stack. Cardiovascular endpoints: blood pressure, lipid profile in chronic studies.
Where to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.